Comparing two radiation plans with chemo and immunotherapy for rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study compares two ways of giving radiation therapy for advanced rectal cancer, combined with a chemotherapy pill and an immunotherapy drug. One approach uses a shorter course of radiation before surgery, and the other uses a longer course; researchers want to see which is more effective and safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have rectal cancer that has grown into or through the muscle layer, and may have spread to nearby lymph nodes, but not to other organs.
- You must have a type of rectal cancer called adenocarcinoma, and your tumor must be within 12 cm of the anal opening.
- You must not have received any prior chemotherapy, radiation, or other cancer treatment for this cancer.
- You must be generally healthy (able to care for yourself) and have normal organ function, with no major heart, autoimmune, or other serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two different radiation regimens (long-course vs. short-course) combined with chemotherapy (CAPOX), an immunotherapy drug (PD-1 antibody), and a COX-2 inhibitor for people with MSS locally advanced rectal cancer. The goal is to see which approach works better in shrinking the tumor before surgery.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
This trial tests whether combining short-course radiation with a chemotherapy regimen (CAPOX) and an immunotherapy drug (QL1706) can help treat rectal cancer that has spread to the liver. It is designed for patients who have not had any prior cancer treatment.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This study compares two different ways of delivering radiation and chemotherapy before surgery for locally advanced rectal cancer. The goal is to see which approach is more effective and safer for people whose cancer has not spread.
This trial tests whether a short course of radiation followed by an immunotherapy drug (PD-L1 inhibitor) plus chemotherapy works as well as or better than a longer radiation course for locally advanced rectal cancer. The goal is to shrink tumors before surgery.
Hear when a new Locally Advanced Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.